RevOpsis and Kemwell Biopharma Announce Partnership to Accelerate Production of Novel Multispecific Biologics
The CDMO’s facilities will be used to accelerate the production for a treatment of nAMD.
Stock.adobe.com
RevOpsis announced a strategic manufacturing partnership with Kemwell Biopharma, a CDMO.1 This move will allow the biopharmaceutical company to utilize the CDMO’s facilities to accelerate development of RO-104, a treatment for neovascular age-related macular degeneration (nAMD).
In a press release, RevOpsis CEO and co-founder Ram Bhandari, MD, said, “Partnering with Kemwell is a pivotal step in accelerating the development of our lead candidate, RO-104, and advancing our pipeline of innovative multispecific biologics. Kemwell's exemplary track record in high-quality biologics manufacturing and their efficiency in reducing timelines, combined with our proprietary Rev-Mod platform, ensures we can deliver transformative therapies to patients efficiently. This collaboration aligns with our mission to develop groundbreaking treatments expeditiously and bring our innovation to patients worldwide."
In the same press release, Kemwell Biopharma CEO Anurag Bagaria said, “We are excited to collaborate with RevOpsis to manufacture and commercialize RO-104. Our expertise in complex protein manufacturing, coupled with RevOpsis' innovative therapeutic approaches, holds great promise for advancing the treatment of retinal vascular diseases. This strategic partnership underscores our commitment to delivering high-quality biologics for patients in need."
This is the latest big move made by the biopharmaceutical company. In May, RevOpsis announced that Dr. Emmett Cunningham had joined its strategic advisory board.2
In a press release issued at the time, Dr. Cunningham said, “I am honored to join RevOpsis as an early investor and Strategic Advisory Board member. My experience is well aligned to contribute to the RevOpsis mission of revolutionizing ophthalmic therapies. I am impressed by the company's dedication to innovation and commitment to improving patient care. I look forward to collaborating with the team to drive their pipeline of transformative treatments forward."
In the same press release, Bhandari said, “We are excited to welcome Dr. Emmett Cunningham to our Strategic Advisory Board. Dr. Cunningham's wealth of experience and deep understanding of the ophthalmic and investment landscapes make him an invaluable asset to the RevOpsis SAB. Dr. Cunningham's guidance will be instrumental as we continue to advance our proprietary Rev-Mod Platform and develop novel treatments for chronic multifactorial diseases, including our current lead candidate RO-104."
In April, RevOpsis announced that it had closed its first seed funding round, having raised a total of $16.5 million.3
In a press release issued at the time, Bhandari stated, “This seed funding round validates our proprietary Rev-Mod platform and facilitates the development of RevOpsis' next generation multispecific antibody platform to address the unmet needs of patients suffering with sight threatening diseases. The proceeds will accelerate our ongoing IND efforts for RO-104. Additionally, the funds will be used to strengthen RevOpsis' research capabilities to further develop a pipeline of first and best-in-class retinal treatments. We are grateful for the support of our investors and excited to continue advancing the RevOpsis mission of bringing responsible and affordable therapeutic innovation to patients worldwide."
Sources
- RevOpsis and Kemwell Biopharma Enter into Strategic Manufacturing Partnership to Expedite Development of Novel Multispecific Biologics. RevOpsis. June 17, 2024. https://www.prnewswire.com/news-releases/revopsis-and-kemwell-biopharma-enter-into-strategic-manufacturing-partnership-to-expedite-development-of-novel-multispecific-biologics-302174227.html
- RevOpsis Welcomes Dr. Emmett Cunningham to Strategic Advisory Board. RevOpsis. May 3, 2024. Accessed June 17, 2024. https://www.prnewswire.com/news-releases/revopsis-welcomes-dr-emmett-cunningham-to-strategic-advisory-board-302135444.html
- RevOpsis Secures $16.5 Million Seed Funding to Advance First-in-Class Tri-Specific Therapy for Neovascular AMD Treatment. RevOpsis. April 25, 2024. Accessed June 17, 2024. https://www.prnewswire.com/news-releases/revopsis-secures-16-5-million-seed-funding-to-advance-first-in-class-tri-specific-therapy-for-neovascular-amd-treatment-302127081.html
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
